MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

11.97 -0.06 (-0.50%)
Official Closing Price Updated: 7:00 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch GARP Candidate in the Pharmaceuticals Space ↗
Via Chartmill
Peter Lynch's GARP Strategy Identifies DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) as a Candidate ↗
Via Chartmill
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Passes Key Peter Lynch Investment Screen ↗
Via Chartmill
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy ↗
Via Chartmill
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test ↗
Via Chartmill
News headline image
Dr. Reddy’s Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
RDY SHAREHOLDER ALERT: Dr. Reddy’s Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Passes Peter Lynch's GARP Investment Filter ↗
Via Chartmill
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy’s Laboratories (RDY)
From Levi & Korsinsky
Via Business Wire
News headline image
Dr. Reddy's Laboratories Q1 Earnings Call Highlights ↗
Dr. Reddy's Laboratories (NYSE:RDY) reported a year-over-year revenue decline and sharply lower profitability for the first quarter of fiscal 2027, as lower lenalidomide sales and semaglutide... 
Via MarketBeat
Topics Earnings
News headline image
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk ↗
Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management... 
Via MarketBeat
News headline image
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call ↗
Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to... 
Via Benzinga
Topics Earnings
News headline image
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
From Dr. Reddy’s Laboratories Limited
Via Business Wire
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Q4 Earnings Call Highlights ↗
Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower... 
Via MarketBeat
Topics Earnings
News headline image
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Screens ↗
Dr. Reddy's Laboratories exemplifies Peter Lynch's GARP strategy with strong earnings growth, a low PEG ratio, and a debt-free balance sheet. 
Via Chartmill
News headline image
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
From Aurigene Oncology Limited
Via Business Wire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Dr. Reddy's Labs fits the Peter Lynch investment model with strong EPS growth, a low PEG ratio, minimal debt, and high ROE, making it a compelling GARP stock. 
Via Chartmill
News headline image
Dr. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch Investment Strategy ↗
Dr. Reddy's Laboratories aligns with Peter Lynch's GARP strategy, showing strong financial health, steady earnings growth, and an attractive valuation with a low PEG ratio. 
Via Chartmill
News headline image
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
From Aurigene Oncology Limited
Via Business Wire
News headline image
Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria ↗
Discover Dr. Reddy's (RDY), a Peter Lynch-style GARP stock with strong earnings growth, low debt, and an attractive PEG ratio for long-term value. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story